Jefferies analyst Stephen Barker downgraded PeptiDream to Hold from Buy with a price target of 1,300 yen, down from 1,600 yen. The downgrade reflects eliminating the estimated contribution from a peptide that Bristol Myers Squibb was developing in Phase 1 trials.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PPTDF: